Overview A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) Status: Completed Trial end date: 2012-09-01 Target enrollment: Participant gender: Summary This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study of NP001 in subjects with ALS. Phase: Phase 2 Details Lead Sponsor: Neuraltus Pharmaceuticals, Inc.